



Fabio Girardi

Nazionalità: Italiana **Data di nascita:** 22/10/1980 **Sesso:** Maschile

Numero di telefono: (+39) 0498215931

Indirizzo e-mail: fabio.girardi@iov.veneto.it

Lavoro: Via Gattamelata 64, 35128 Padova (Italia)

ESPERIENZA LAVORATIVA

Dirigente Medico a tempo indeterminato

Istituto Oncologico Veneto IRCCS [01/09/2020 – Attuale]

Città: Padova

Paese: Italia

Honorary (Clinical) Assistant Professor in Cancer Epidemiology

London School of Hygiene and Tropical Medicine [14/12/2021 – Attuale]

Città: Londra

Paese: Regno Unito

Dirigente Medico a tempo indeterminato

Azienda ULSS 2 Marca Trevigiana – Regione Veneto [01/03/2020 – 31/08/2020]

Città: Treviso

Paese: Italia

ESMO Examination

European Society for Medical Oncology [28/09/2019]

Città: Barcellona

Paese: Spagna

Honorary Consultant Oncologist

University College London Hospitals NHS Foundation Trust [08/08/2018 – 01/05/2021]

Città: Londra

Paese: Regno Unito

Full registration with a licence to practise and entry on the Specialist Register

General Medical Council [20/04/2016 – Attuale]

Città: Londra

Paese: Regno Unito

Dirigente Medico a tempo indeterminato

Azienda ULSS 2 Marca Trevigiana – Regione Veneto [01/02/2013 – 30/08/2017]

Città: Castelfranco Veneto

Paese: Italia

Dirigente Medico a tempo indeterminato

Azienda USL Bologna - Regione Emilia Romagna [01/03/2012 – 31/01/2013]

Città: Bologna

Paese: Italia

Dirigente Medico a tempo indeterminato

Azienda ULSS 2 Marca Trevigiana – Regione Veneto [03/05/2010 – 02/2012]

Città: Castelfranco Veneto

Paese: Italia

Esame di Stato per l'abilitazione professionale

Università degli Studi di Padova [15/02/2006]

Città: Padova

Paese: Italia

ISTRUZIONE E FORMAZIONE

PhD in Epidemiology and Population Health (dottorato di ricerca)

London School of Hygiene and Tropical Medicine [25/09/2017 – 25/04/2021]

Indirizzo: Keppel Street , WC1E 7HT Londra (Regno Unito)

Campi di studio: Epidemiologia, Biostatistica, Salute Pubblica

Livello EQF: Livello 8 EQF

Tesi: "Global surveillance of survival from intrinsic brain tumours diagnosed during 2000-2014: trends by age and histology". Supervisors: Professor Claudia Allemani, Professor Michel Coleman

Competenze acquisite: analisi indipendente di grandi datasets provenienti da 300+ registri oncologici di popolazione in 70 paesi, nel contesto dello studio **CONCORD-3**. Uso di tecniche statistiche avanzate per analisi di sopravvivenza.

Master of Philosophy in Epidemiology (laurea magistrale)

University of Cambridge [06/10/2015 – 29/09/2016]

Indirizzo: The Old Schools, Trinity Lane, CB2 1TN Cambridge (Regno Unito)

Campi di studio: Epidemiologia, Biostatistica

Livello EQF: Livello 7 EQF

Tesi: "Using data from the EMBRACE prospective cohort of families with BRCA1/BRCA2 mutations to estimate cancer risks for family members who do not carry the family mutations". Supervisor: Professor Antonis Antoniou

Apprendimento di tecniche di biostatistica avanzata per l'analisi epidemiologica di dati di popolazione.

Diploma di Specializzazione in Oncologia Medica

Università degli Studi di Padova [01/01/2006 – 14/01/2010]

Indirizzo: Via VIII Febbraio 2, 35122 Padova (Italia)

Voto finale: 70/70 con lode – Livello EQF: Livello 8 EQF

Tesi: "Lo stato di metilazione del gene O6-Metilguanina DNA Metiltransferasi (MGMT) come fattore prognostico per i pazienti affetti da astrocitoma anaplastico". Relatore: Professor Fausto Adami

Laurea in Medicina e Chirurgia

Università degli Studi di Padova [01/10/1999 – 29/09/2005]

Indirizzo: Via VIII Febbraio 2, 35122 Padova (Italia)

Voto finale: 110/110 con lode – Livello EQF: Livello 7 EQF

Tesi: "Il repertorio del B-Cell Receptor e lo stato mutazionale dei geni VH nei pazienti con leucemia linfatica cronica B". Relatore: Professor Gianpietro Semenzato

COMPETENZE LINGUISTICHE

Lingua madre: **italiano**

Altre lingue:

Inglese; 14/11/2021: International English Language Testing System (IELTS): CEFR C2

Tedesco; 17/6/2015: Goethe-Zertifikat: CEFR B1

ASCOLTO B1 LETTURA B1 SCRITTURA B1

ASCOLTO C2 LETTURA C2 SCRITTURA C1

PRODUZIONE ORALE B1 INTERAZIONE ORALE B1

PRODUZIONE ORALE C1 INTERAZIONE ORALE C1

COMPETENZE DIGITALI

Ottime conoscenze del pacchetto Office (Word, Power Point, Excel) / StatSoft Statistica STATA / Reference Management softwares Zotero EndNote Mendeley

PUBBLICAZIONI

Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3)

Neuro-Oncology, 2022

[Girardi E](#), Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard J, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C, CONCORD Working Group

Global survival trends for brain tumours, by histology: analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3)

Neuro-Oncology, 2022

[Girardi E](#), Di Carlo V, Stiller C, Gatta G, Woods RR, Visser O, Lacour B, Tucker TC, Coleman MP, Allemani C, CONCORD Working Group

Reply to "Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates - A European perspective to Girardi et al"

Neuro-Oncology, 2022; 24:1208-1209

[Girardi E](#), Coleman MP, Allemani C

Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries

Lancet Child Adolesc Health, 2022; 6:409-431

Ssenyonga N, Stiller C, Nakata K, Shalkow J, Redmond S, Bulliard J, [Girardi E](#), Fowler C, Marcos-Gragera R, Bonaventure A, Saint-Jacques N, Minicozzi P, De P, Rodríguez-Barranco M, Larønningen S, Di Carlo V, Mägi M, Valkov M, Seppä K, Wyn Huws D, Coleman MP, Allemani C, CONCORD Working Group

Does the morphology of cutaneous melanoma help explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3)

Br J Dermatol, 2022; 187:364-380

Di Carlo V, Stiller CA, Eisemann N, Bordoni A, Matz M, Curado MP, Daubisse-Marliac L, Valkov M, Bulliard J, Morrison D, Johnson C, [Girardi E](#), Marcos-Gragera R, Šekeriya M, Larønningen S, Sirri E, Coleman MP, Allemani C, CONCORD Working Group

Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials

ESMO Open, 2022; 7:100433

Guarneri V, Griguolo G, Miglietta F, Conte PF, Dieci MV, [Girardi E](#)

The histology of brain tumours for 67,331 children and 671,085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3)

Neuro-Oncology, 2021; 23:1765-1776

[Girardi E](#), Rous B, Stiller CA, Gatta G, Fersht N, Storm HH, Rodrigues JR, Herrmann C, Marcos-Gragera R, Peris-Bonet R, Valkov M, Weir HK, Woods RR, You H, Cueva PA, De P, Di Carlo V, Johannesen TB, Lima CA, Lynch CF, Coleman MP, Allemani C, CONCORD Working Group

Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: survival analyses of the CHER-Lob trial

European Journal of Cancer, 2021; 153:133-141

Guarneri V, Dieci MV, Griguolo G, Miglietta F, [Girardi E](#), Bisagni G, Generali DG, Cagossi K, Sarti S, Frassoldati A, Gianni L, Cavanna L, Pinotti G, Musolino A, Piacentini F, Cinieri S, Prat A, Conte P, CHER-Lob study team

Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3)

JNCI Cancer Spectrum, 2020; 4:pkaa078

Di Carlo V, Estève J, Johnson C, [Girardi E](#), Weir HK, Wilson RJ, Minicozzi P, Cress RD, Lynch CF, Pawlish KS, Rees JR, Coleman MP, Allemani C; US CONCORD Working Group

Global trends in survival from astrocytic tumours in adolescents and young adults: a systematic review

JNCI Cancer Spectrum, 2020; 4:pkaa049

[Girardi E](#), Allemani C, Coleman MP

Sustainable care for children with cancer: a Lancet Oncology Commission

Lancet Oncology, 2020; 21:e185-224

Atun R, Bhakta N, Denburg A, Frazier AL, Friedrich P, Gupta S, Lam CG, Ward ZJ, Yeh JM, Allemani C, Coleman MP, Di Carlo V, Loucaides E, Fitchett E, [Girardi E](#), Horton SE, Bray F, Steliarova-Foucher E, Sullivan R, Aitken JF, Banavali S, Binagwaho A, Alcasabas P, Antillon F, Arora RS, Barr RD, Bouffet E, Challinor J, Fuentes-Alabi S, Gross T, Hagander L, Hoffman RI, Herrera C, Kutluk T, Marcus KJ, Moreira C, Pritchard-Jones K, Ramirez O, Renner L, Robison LL, Shalkow J, Sung L, Yeoh A, Rodriguez-Galindo C

Colorectal cancer incidence among young adults in England: trends by anatomical sub-site and deprivation

PLoS One, 2019; 14:e0225547

Exarchakou A, Donaldson LJ, [Girardi E](#), Coleman MP

World-wide trends in survival from common childhood brain tumours: a systematic review

JCO Global Oncology, 2019; 5:1-25

[Girardi E](#), Allemani C, Coleman MP

Global childhood cancer survival estimates and priority-setting: a simulation-based analysis

Lancet Oncology, 2019; 20:972-983

Ward ZJ, Yeh JM, Bhakta N, Frazier AL, [Girardi E](#), Atun R

Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study

Genetics in Medicine, 2018; 20:1575-1582

[Girardi E](#), Barnes DR, Barrowdale D, Frost D, Brady AF, Miller C, Henderson A, Donaldson A, Murray A, Brewer C, Pottinger C, Evans DG, Eccles D; EMBRACE, Laloo F, Gregory H, Cook J, Eason J, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Eeles R, Davidson R, Snape K, Easton DF, Antoniou AC

Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies

Oncologist, 2010; 15:683-694

[Girardi E](#), Franceschi E, Brandes AA

Bevacizumab in brain tumors: ready for primetime

Future Oncology, 2009; 5:1183-1184

Franceschi E, Tosoni A, [Girardi E](#), Brandes AA

CONFERENZE E SEMINARI

ESMO Congress

[Barcellona (Spagna), 28/09/2019]

Poster presenter. Central Nervous System Tumours Poster Session, abstract 410P

[Girardi E](#), Fersht N, Coleman MP, Allemani C, CONCORD Working Group. Global trends in population-based survival for 303,169 adults diagnosed with glioblastoma in 44 countries during 2000-2014 (CONCORD-3)

NAACCR /IACR Combined Annual Conference

[Vancouver (Canada), 13/06/2019]

Oral presenter. Concurrent Session 5B, Survival and Brain and CNS

[Girardi E](#), Di Carlo V, Coleman MP, Allemani C, CONCORD Working Group. Global trends in survival from astrocytoma in young people: a population-based analysis (CONCORD-3)

NAACCR /IACR Combined Annual Conference

[Vancouver (Canada), 11/06/2019]

Poster presenter. Poster Session, abstract PS-5

[Girardi E](#), Johnson CJ, Tucker TC, Coleman MP, Allemani C, US CONCORD Working Group. Radiotherapy in patients affected by glioblastoma: does time to treatment impact on survival? A population-based analysis using data from CONCORD-3

ESMO Congress

[Monaco (Germania), 22/10/2018]

Poster presenter. Public Health Policy Poster Session, abstract 1597P

[Girardi E](#), Di Carlo V, Bonaventure A, Allemani C, Coleman MP, CONCORD Working Group. Worldwide trends in survival from childhood glioma 2000-2014 (CONCORD-3): preliminary findings and plans for further research

ESMO Congress

[Monaco (Germania), 22/10/2018]

Poster presenter. Central Nervous System Tumours Poster Session, abstract 383P

[Girardi E](#), Di Carlo V, Bonaventure A, Allemani C, Coleman MP, CONCORD Working Group. Worldwide trends in survival from adult glioma 2000-2014 (CONCORD-3): impact of morphology

ASCO Annual Meeting

[Chicago (Stati Uniti), 05/06/2017]

Poster presenter. Cancer Prevention, Genetics and Epidemiology Poster Session, abstract 1558

[Girardi E](#), Barnes DR, Barrowdale D, Frost D, Easton DF, Antoniou AC, EMBRACE Collaborators. Risk of breast or ovarian cancer in family members who do not carry the BRCA1 or BRCA2 family mutation: findings from the EMBRACE study

PROGETTI

CONCORD Programme

[25/09/2017 – Attuale]

Collaborazione internazionale di 70 paesi in 5 continenti per la sorveglianza globale dei trends di sopravvivenza per 18 tipi di neoplasia. Sede: London School of Hygiene and Tropical Medicine (Londra, Regno Unito).

Ruolo: membro del team analitico centrale

RICONOSCIMENTI

Merit Award

[29/09/2019]

European Society for Medical Oncology

Merit Award

[22/10/2018]

European Society for Medical Oncology

Jane Davidson & Paul O'Gorman Doctoral Fellowship

[20/03/2017]

London School of Hygiene and tropical Medicine (Regno Unito)

Medical Research Council Master of Philosophy Scholarship

[23/07/2015]

University of Cambridge (Regno Unito)

CORSI BREVI

Global Health Short Course. Imperial College School of Public Health. Londra (Regno Unito)

[23/06/2014 – 27/06/2014]

Advanced Medical Life Support. National Association of Emergency Medical Technicians. Azienda Ospedaliera di Padova. Padova (Italia)

[29/10/2008 – 30/10/2008]

SOCIETÀ SCIENTIFICHE

European Society for Medical Oncology (ESMO)

[2018 – Attuale]

GRANT APPLICATION PEER REVIEW

Integrated Research Action Programme (PAIR)

Institut National du Cancer (INCa), France

Periodo: 25/3/2021-29/9/2021

Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n. 196 - "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 - "Regolamento europeo sulla protezione dei dati personali".